<code id='4793756ADF'></code><style id='4793756ADF'></style>
    • <acronym id='4793756ADF'></acronym>
      <center id='4793756ADF'><center id='4793756ADF'><tfoot id='4793756ADF'></tfoot></center><abbr id='4793756ADF'><dir id='4793756ADF'><tfoot id='4793756ADF'></tfoot><noframes id='4793756ADF'>

    • <optgroup id='4793756ADF'><strike id='4793756ADF'><sup id='4793756ADF'></sup></strike><code id='4793756ADF'></code></optgroup>
        1. <b id='4793756ADF'><label id='4793756ADF'><select id='4793756ADF'><dt id='4793756ADF'><span id='4793756ADF'></span></dt></select></label></b><u id='4793756ADF'></u>
          <i id='4793756ADF'><strike id='4793756ADF'><tt id='4793756ADF'><pre id='4793756ADF'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:61922
          Sammy Kimball for STAT

          Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

          advertisement

          For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          comprehensive

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO
          The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

          MollyFerguson/STATHappyGroundhogDayeve.SometakesandthoughtsonBluebirdBio’squestforgenetherapyprofits

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Merck CEO won’t testify in Senate, citing no expertise in drug prices

          Sen.BernieSanderstoldreportersthatMerck'sCEOrefusedtotestifyoveralackofexpertiseindrugpricing.Mariam